Barrios-Araya Silvia, Espinoza-Coya María Elisa, Ñuñez-Gómez Kelly, Sepúlveda-Palamara Rodrigo, Molina-Muñoz Yerko
Escuela de Enfermería, Pontificia Universidad Católica de Chile, Santiago, Chile.
Unidad Procedimiento Nefrológico, Hospital Clínico Red de Salud, Santiago, Chile.
Rev Med Chil. 2019 Apr;147(4):409-415. doi: 10.4067/S0034-98872019000400409.
In critical patients with acute renal failure, intermittent diffusive renal replacement techniques cause hemodynamic problems due to their high depurative efficiency. This situation is avoided using continuous low efficiency therapies, which are expensive, prevent patient mobilization and add hemorrhagic risk due to systemic anticoagulation. Intermittent and prolonged hemodiafiltration (HDF) has the depurative benefits of diffusion, plus the positive attributes of convection in a less expensive therapy.
To report our experience with intermittent and prolonged on-line HDF in critically ill patients.
During 2016, HDF therapies performed on critical patients with indication of renal replacement therapy were characterized. The hemodynamic profile was evaluated (doses of noradrenaline, blood pressure, heart rate and perfusion parameters).
Fifty-one therapies were performed in 25 critical patients, aged 58 ± 11 years (28% women), with an APACHE II score of 22.1 ±10. The average time of the therapies was 4.15 hours (range 3-8 hours), the replacement volume was 75 ± 18 mL/kg/h and ultrafiltration rate was 226 ± 207 mL/h. The mean initial, maximum and final noradrenaline doses were 0.07 ± 0.1, 0.13 ±0.18 and 0.09 ±0.16 μg/kg/min respectively. No differences between patients with low, medium and high doses of noradrenaline or dose increases during therapy, were observed. The greatest decrease in mean arterial pressure was 15.3% and the maximum increase in heart rate was 12.8%. Anticoagulation was not required in 88% of therapies.
High-volume intermittent or prolonged HDF is an effective therapy in critical patients, with good hemodynamic tolerability, lower costs and avoidance of systemic anticoagulation risks.
在急性肾衰竭的重症患者中,间歇性弥散性肾脏替代技术因其高净化效率会导致血流动力学问题。采用持续低效治疗可避免这种情况,但此类治疗费用高昂,会妨碍患者活动,且因全身抗凝会增加出血风险。间歇性和延长性血液透析滤过(HDF)具有弥散的净化优势,同时在费用较低的治疗中还具有对流的积极特性。
报告我们在重症患者中进行间歇性和延长性在线HDF的经验。
对2016年期间对有肾脏替代治疗指征的重症患者进行的HDF治疗进行了特征分析。评估了血流动力学指标(去甲肾上腺素剂量、血压、心率和灌注参数)。
对25例重症患者进行了51次治疗,患者年龄为58±11岁(28%为女性),急性生理与慢性健康状况评分系统(APACHE II)评分为22.1±10。治疗的平均时间为4.15小时(范围为3 - 8小时),置换量为75±18 mL/kg/h,超滤率为226±207 mL/h。去甲肾上腺素的平均初始、最大和最终剂量分别为0.07±0.1、0.13±0.18和0.09±0.16μg/kg/min。未观察到去甲肾上腺素低、中、高剂量患者之间或治疗期间剂量增加情况的差异。平均动脉压最大降幅为15.3%,心率最大增幅为12.8%。88%的治疗无需抗凝。
大容量间歇性或延长性HDF对重症患者是一种有效的治疗方法,具有良好的血流动力学耐受性、较低的成本且可避免全身抗凝风险。